GCB Newsletter Volume 3: Fall 2018

artistic rendering of a strand of DNA
GCB News

GCB Newsletter Volume 3: Fall 2018

Highlights to the current issue include:

  • Targeted epigenome editing as 'next generation drugs' for Parkinson's disease
  • New Genomic Medicine Collaboratory to serve as nexus for genetics, genomics community
  • Element Genomics acquired by global pharmaceuticals company
  • New Funding
  • Chris Nelson earns K99 grant
  • New undergrad course offers comprehensive overview of genome science tech
  • Tagliafierro receives grant to examine associations between aging, genetics, and Alzheimer's disease
  • Inaugural Summer Scholars Program Wrap Ups in End-of-Summer Poster Session
  • New GCB Collaboration Brings German Researchers, Scholars Stateside
  • Updates from the Cores
  • 2018 Fall SOM Core Facility Voucher Program

Read more

Related News

red blood cells

New Finding Could Unmask Blood Doping in Athletes

RNA changes mark old blood cells among new ones, foiling self-transfusions

Terrie Moffitt

Terrie Moffitt elected to National Academy of Medicine

Co-Director of Landmark Longitudinal Study in New Zealand

Greg Crawford, Kris Woods, Tim Reddy, and Charlie Gersbach

From Innovation to Impact

When four Duke researchers developed an innovative technique for exploring the non-coding genome—the 98 percent of our DNA that does not encode protein sequences, often called the genome’s “dark matter”—the implications were clear.